XORTX Therapeutics
XRTX
3 hedge funds and large institutions have $8.01K invested in XORTX Therapeutics in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.15% less ownership
Funds ownership: 0.23% → 0.07% (-0.15%)
70% less capital invested
Capital invested by funds: $26.6K → $8.01K (-$18.6K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$261 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$18.3K |
XRTX Hedge Fund Activity: Q3 2023 in Review
3 of the 6,311 institutional investors tracked by Wall St. Rank reported a position in XORTX Therapeutics (XRTX) for Q3 2023, worth a combined $8.01K — down 70% from $26.6K a quarter earlier.
Fund positioning in XRTX was balanced in Q3 2023: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was Royal Bank of Canada, opening a new position worth an estimated $261. The largest seller was Citadel Advisors, exiting entirely with an estimated $18.3K sold.
- 3 institutional investors held XORTX Therapeutics (XRTX) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $8.01K of XORTX Therapeutics stock for Q3 2023, down 70% quarter-over-quarter.
- 1 fund opened new XORTX Therapeutics positions in Q3 2023 and 1 closed out, a net change of 0 holders.
- The largest XORTX Therapeutics buyer in Q3 2023 was Royal Bank of Canada, an estimated $261 added.
- The largest XORTX Therapeutics seller in Q3 2023 was Citadel Advisors, an estimated $18.3K sold.
Based on aggregated 13F filings for Q3 2023.